We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Determine Efficacy and Safety of CTL019 in Pediatric Patients With Relapsed and Refractory B-cell ALL (ELIANA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02435849
Recruitment Status : Active, not recruiting
First Posted : May 6, 2015
Last Update Posted : March 16, 2018
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )